利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.033 秒)

    DISEASE PATHWAY-BASED METHOD TO GENERATE BIOMARKER PANELS TAILORED TO SPECIFIC THERAPEUTICS FOR INDIVIDUALIZED TREATMENTS
    5.
    发明公开
    DISEASE PATHWAY-BASED METHOD TO GENERATE BIOMARKER PANELS TAILORED TO SPECIFIC THERAPEUTICS FOR INDIVIDUALIZED TREATMENTS 审中-公开

    公开(公告)号：US20230258625A1

    公开(公告)日：2023-08-17

    申请号：US18137113

    申请日：2023-04-20

    申请人： Peter Blume-Jensen

    发明人： Peter Blume-Jensen

    IPC分类号： G01N33/50

    CPC分类号： G01N33/5041 ,  G01N2440/14 ,  G01N2800/7028

    摘要： The increased efficacy and reduced unwanted side effects of drugs can be insured by treating only responsive patients. In an embodiment of the invention, signaling pathways that a particular drug interferes with, are derive together with predictive biomarkers and dynamic biomarker that can read the activity of these pathways before and after drug treatment in order to select a responder patient population. In an alternative embodiment of the invention, certain core pathways that the drug does not interfere with and that are known to be causally involved in a particular disease(s) can be identified, and derive the biomarkers for those to be able to exclude these patients that suffer from a disease in which those drug non effected pathways are involved from being treated with the specific drug in question.

    DISEASE PATHWAY-BASED METHOD TO GENERATE BIOMARKER PANELS TAILORED TO SPECIFIC THERAPEUTICS FOR INDIVIDUALIZED TREATMENTS
    6.
    发明申请
    DISEASE PATHWAY-BASED METHOD TO GENERATE BIOMARKER PANELS TAILORED TO SPECIFIC THERAPEUTICS FOR INDIVIDUALIZED TREATMENTS 审中-公开

    公开(公告)号：US20190317077A1

    公开(公告)日：2019-10-17

    申请号：US16430103

    申请日：2019-06-03

    申请人： Peter Blume-Jensen

    发明人： Peter Blume-Jensen

    IPC分类号： G01N33/50

    摘要： The increased efficacy and reduced unwanted side effects of drugs can be insured by treating only responsive patients. In an embodiment of the invention, signaling pathways that a particular drug interferes with, are derive together with predictive biomarkers and dynamic biomarker that can read the activity of these pathways before and after drug treatment in order to select a responder patient population. In an alternative embodiment of the invention, certain core pathways that the drug does not interfere with and that are known to be causally involved in a particular disease(s) can be identified, and derive the biomarkers for those to be able to exclude these patients that suffer from a disease in which those drug non effected pathways are involved from being treated with the specific drug in question.

    DISEASE PATHWAY-BASED METHOD TO GENERATE BIOMARKER PANELS TAILORED TO SPECIFIC THERAPEUTICS FOR INDIVIDUALIZED TREATMENTS
    7.
    发明申请
    DISEASE PATHWAY-BASED METHOD TO GENERATE BIOMARKER PANELS TAILORED TO SPECIFIC THERAPEUTICS FOR INDIVIDUALIZED TREATMENTS 审中-公开
    基于路径路径的生物标记生物标记面板方法，可用于个性化治疗的特定治疗方法

    公开(公告)号：US20090155804A1

    公开(公告)日：2009-06-18

    申请号：US12331356

    申请日：2008-12-09

    申请人： Peter Blume-Jensen

    发明人： Peter Blume-Jensen

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6883

    摘要： The increased efficacy and reduced unwanted side effects of drugs can be insured by treating only responsive patients. In an embodiment of the invention, signaling pathways that a particular drug interferes with, are derive together with predictive biomarkers and dynamic biomarker that can read the activity of these pathways before and after drug treatment in order to select a responder patient population. In an alternative embodiment of the invention, certain core pathways that the drug does not interfere with and that are known to be causally involved in a particular disease(s) can be identified, and derive the biomarkers for those to be able to exclude these patients that suffer from a disease in which those drug non effected pathways are involved from being treated with the specific drug in question.

    摘要翻译： 通过仅治疗反应性患者可以确保药物的功效增加和减少不需要的副作用。 在本发明的一个实施方案中，特定药物干扰的信号传导途径与预测生物标志物和动态生物标志物一起导出，其可以在药物治疗之前和之后阅读这些途径的活性，以选择应答者患者群体。 在本发明的替代实施方案中，可以鉴定药物不干扰并且已知与某种特定疾病有因果关系的某些核心途径，并且为那些能够排除这些患者的生物标志物得出 患有这些药物非影响途径参与与所讨论的具体药物治疗的疾病。

    DISEASE PATHWAY-BASED METHOD TO GENERATE BIOMARKER PANELS TAILORED TO SPECIFIC THERAPEUTICS FOR INDIVIDUALIZED TREATMENTS
    8.
    发明申请
    DISEASE PATHWAY-BASED METHOD TO GENERATE BIOMARKER PANELS TAILORED TO SPECIFIC THERAPEUTICS FOR INDIVIDUALIZED TREATMENTS 审中-公开
    基于路径路径的生物标记生物标记面板方法，可用于个性化治疗的特定治疗方法

    公开(公告)号：US20170067877A9

    公开(公告)日：2017-03-09

    申请号：US13954080

    申请日：2013-07-30

    申请人： Peter Blume-Jensen

    发明人： Peter Blume-Jensen

    IPC分类号： G01N33/50

    CPC分类号： G01N33/5041 ,  G01N2440/14 ,  G01N2800/7028

    摘要： The increased efficacy and reduced unwanted side effects of drugs can be insured by treating only responsive patients. In an embodiment of the invention, signaling pathways that a particular drug interferes with, are derive together with predictive biomarkers and dynamic biomarker that can read the activity of these pathways before and after drug treatment in order to select a responder patient population. In an alternative embodiment of the invention, certain core pathways that the drug does not interfere with and that are known to be causally involved in a particular disease(s) can be identified, and derive the biomarkers for those to be able to exclude these patients that suffer from a disease in which those drug non effected pathways are involved from being treated with the specific drug in question.

    摘要翻译： 通过仅治疗反应性患者可以确保药物的功效增加和减少不需要的副作用。 在本发明的一个实施方案中，特定药物干扰的信号传导途径与预测生物标志物和动态生物标志物一起导出，其可以在药物治疗之前和之后阅读这些途径的活性，以选择应答者患者群体。 在本发明的替代实施方案中，可以鉴定药物不干扰并且已知与某种特定疾病有因果关系的某些核心途径，并且为那些能够排除这些患者的生物标志物得出 患有这些药物非影响途径参与与所讨论的具体药物治疗的疾病。

    DISEASE PATHWAY-BASED METHOD TO GENERATE BIOMARKER PANELS TAILORED TO SPECIFIC THERAPEUTICS FOR INDIVIDUALIZED TREATMENTS
    9.
    发明申请
    DISEASE PATHWAY-BASED METHOD TO GENERATE BIOMARKER PANELS TAILORED TO SPECIFIC THERAPEUTICS FOR INDIVIDUALIZED TREATMENTS 审中-公开

    公开(公告)号：US20150037810A1

    公开(公告)日：2015-02-05

    申请号：US13954080

    申请日：2013-07-30

    申请人： Peter Blume-Jensen

    发明人： Peter Blume-Jensen

    IPC分类号： G01N33/50

    CPC分类号： G01N33/5041 ,  G01N2440/14 ,  G01N2800/7028

    摘要： The increased efficacy and reduced unwanted side effects of drugs can be insured by treating only responsive patients. In an embodiment of the invention, signaling pathways that a particular drug interferes with, are derive together with predictive biomarkers and dynamic biomarker that can read the activity of these pathways before and after drug treatment in order to select a responder patient population. In an alternative embodiment of the invention, certain core pathways that the drug does not interfere with and that are known to be causally involved in a particular disease(s) can be identified, and derive the biomarkers for those to be able to exclude these patients that suffer from a disease in which those drug non effected pathways are involved from being treated with the specific drug in question.